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Abstract
The apelinergic system has a widespread expression in the
central nervous system (CNS) including the paraventricular
nucleus, supraoptic nucleus and median eminence, and
isolated cells of the anterior lobe of the pituitary. This pattern
of expression in hypothalamic nuclei known to contain
corticotrophin-releasing factor (CRF) and vasopressin (AVP)
and to co-ordinate endocrine responses to stress has
generated interest in a role for apelin in the modulation of
stress, perhaps via the regulation of hormone release from
the pituitary. In this study, to determine whether apelin
has a central role in the regulation of CRF and AVP
neurones, we investigated the effect of i.c.v. administration of
pGlu-apelin-13 on neuroendocrine function in male mice
pre-treated with the CRF receptor antagonist, a-helical
CRF9–41, and in mice-lacking functional AVP V1b receptors
(V1bR KO). Administration of pGlu-apelin-13 (1 mg/kg
i.c.v.) resulted in signiﬁcant increases in plasma ACTH and
corticosterone (CORT), which were signiﬁcantly reduced
by pre-treatment with a-helical CRF9–41, indicating the
involvement of a CRF-dependent mechanism. Additionally,
pGlu-apelin-13-mediated increases in both plasma ACTH
and CORT were signiﬁcantly attenuated in V1bR KO
animals when compared with wild-type controls, indicating
a role for the vasopressinergic system in the regulation of
the effects of apelin on neuroendocrine function. Together,
these data conﬁrm that the in vivo effects of apelin on
hypothalamic–pituitary–adrenal neuroendocrine function
appear to be mediated through both CRF- and AVP-
dependent mechanisms.
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Introduction
The apelin peptide, isolated from extracts of bovine stomach
(Tatemoto et al. 1998), selectively binds to the G-protein-
coupled apelin receptor (APJ; O’Dowd et al. 1993). Apelin, a
36-amino acid peptide, is derived from a 77-amino acid
precursor, preproapelin (Tatemoto et al. 1998, Lee et al. 2000).
Although initial studies suggested that apelin-36 was the
predominant cleavage product in vivo, subsequent studies have
suggested that other cleavage products, notably the pyroglu-
tamyl form of apelin-13 (pGlu-apelin-13) and apelin-17, may
be more abundant in the rat (De Mota et al. 2004, Reaux-Le
Goazigo et al. 2004). These cleavage products have greater
afﬁnity for APJ (Medhurst et al. 2003) and exhibit greater
biological activity than the parent peptide on extracellular
acidiﬁcation rates, promote APJ internalisation and strongly
inhibit forskolin-stimulated cAMP production (Medhurst
et al. 2003, El Messari et al. 2004).
The apelinergic system has a widespread expression in the
CNS, including the paraventricular nucleus (PVN), preoptic
area, periventricular hypothalamus and ventromedial and
dorsomedial nuclei (Lee et al. 2000), while high densities of
apelin immunoreactive ﬁbres and cell bodies have been
detected in the PVN, supraoptic nucleus (SON), the median
eminence (Reaux et al. 2002) and in the posterior pituitary
(Brailoiu et al. 2002). Outside the CNS, apelin immuno-
reactivity and mRNA are present in vascular endothelial cells
(Kleinz & Davenport 2004) and other peripheral tissues such
as heart, mammary gland, lung and adrenal (Habata et al.
1999, O’Carroll et al. 2000). The pattern of expression of the
rat receptor implies that APJ has tissue-speciﬁc functions in
adult animals. High levels of APJ mRNA expression are
found in the brain, the pineal gland, the parenchyma of the
lung, the heart and in isolated cells of the anterior lobe of the
pituitary (O’Carroll et al. 2000). APJexpression is restricted in
the CNS and is particularly striking in the medial
parvocellular regions of the hypothalamic PVN (pPVN)
and scattered magnocellular neurones of the PVN (mPVN)
and SON (De Mota et al. 2000, O’Carroll et al. 2000),
sites that control hypothalamic–pituitary–adrenal (HPA)
axis and hypothalamo-neurohypophysial system activity
respectively (Ynag et al. 1977). APJ mRNA and apelin
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vasopressinergic neurones originating from the SON and
mPVN and projecting to the posterior pituitary (Reaux et al.
2001, O’Carroll & Lolait 2003), where the two peptides are
segregated within distinct subcellular compartments
(Reaux-Le Goazigo et al. 2004). Extrahypothalamic
structures such as the piriform cortex, the dentate gyrus,
the nucleus of the lateral olfactory tract and the dorsal raphe
nucleus also express APJ mRNA (De Mota et al. 2000).
The key CNS site integrating neuroendocrine adjust-
ments to stress is the hypothalamic PVN. This nucleus is
comprised of two major neurosecretory components – the
mPVN and pPVN subdivisions. Neurones originating from
the more medially situated pPVN (where vasopressin (AVP)
is co-localised in a proportion of corticotrophin-releasing
factor (CRF) neurones; Tramu et al. 1983) project to the
median eminence where, in response to stress, CRF and
AVP are released from nerve terminals into the portal
vessels bathing the anterior pituitary. CRF and AVP
stimulate ACTH secretion by interacting with the CRF-
type 1 (CRFR1) and AVP V1b (V1bR) receptors
respectively, on the pituitary corticotrope (Gillies et al.
1982). ACTH in turn potently induces the secretion of
glucocorticoids (corticosterone (CORT) in rodents) by the
adrenal cortex. Regulation of CORT via ACTH secretion
is critical for life and is necessary for the mammalian
response to stress.
In the HPA axis, the presence of apelin and APJ
transcripts and immunoreactivity in hypothalamic nuclei
known to contain AVP and CRF and to co-ordinate
endocrine responses to stress suggests that apelin may play a
role in the control of anterior hormone release. Central,
i.e. administration (i.c.v.) of apelin increases c-fos expression
in the PVN (Kagiyama et al. 2005), and appears to have a
role in the regulation of AVP and CRF neurones as it has
been found to stimulate both AVP and CRF release from
hypothalamic explants in vitro (Taheri et al. 2002), effects
consistent with activation of PVN neurones and stimulation
of the stress axis. This role was conﬁrmed by increased
levels of APJ mRNA resulting from acute and chronic
stress and following adrenalectomy (O’Carroll et al. 2003).
The involvement of apelin in the regulation of CRF
neurones was substantiated by physiological experiments
showing apelin-stimulated basal CORT secretion in rats to
be partially blocked by pre-treatment with a CRF
antagonist, a-helical CRF9–41 ( Jaszberenyi et al. 2004);
however, the role of additional mediators such as AVP
cannot be excluded.
In this study, to determine whether apelin has a central
role in the regulation of CRF and AVP neurones,
we investigated the effect of i.c.v. administration of
pGlu-apelin-13 on neuroendocrine function in male
mice pre-treated with the CRF receptor antagonist,
a-helical CRF9–41, and in mice lacking functional AVP
V1bRs (V1bR KO).
Materials and Methods
Animals
Male adult (8–12 weeks) mice (a mix of the C57BL/6J and
129!1/SvJ strains) were used for in vivo experiments. For
V1bR KO experiments, male adult littermates of crosses
using mice heterozygous for the AVP V1bR mutation were
used. Animals were group-housed (two to four per cage)
under controlled light conditions (12 h light:12 h darkness
cycle, lights on at 0700 h) and temperature (21G2 8C) with
free access to standard laboratory chow and water. Studies
were performed between 0900 and 1200 h. All procedures
were conducted in accordance with the Animal Scientiﬁc
Procedures Act (1986) United Kingdom and the appropriate
University of Bristol Ethical Review Process.
Surgical procedure
Micewereanaesthetisedwithisoﬂurane.Permanent23-gauge
stainless steel guide cannulae (Coopers Needleworks,
Birmingham, UK) were stereotactically placed into the lateral
ventricle (AP, K0.8; LM, C1.0; DV, K2.5 mm from
bregma). Guide cannulae were secured with dental cement
and two tether screws (Precision Technology Supplies, East
Grinstead, UK). A 29-gauge stainless steel stylet was inserted
down the guide cannula to ensure patency. On completion of
surgery,animalsweresinglehousedinacleancage,placedona
heatpad (36G1 8C) and administered antibiotics (Baytril,
BayerUK).Animalswereallowedtorecoverforaminimumof
7 days before being used in experiments. To verify correct
positioning, methylene blue was subsequently injected into
decapitated heads and the brains dissected.
On the day of injection, stylets were removed from the
guide cannulae and a 30-gauge stainless steel injection needle
(40 mmlong,CoopersNeedleworks)inserteddowntheguide
cannula, projecting 0.5 mm below the tip. The injection
needle was attached to a gas-tight 10 ml Hamilton micro-
syringe (Fisher Scientiﬁc, Loughborough, UK) via 30 cm of
ﬂexible portex tubing (0.28 mm internal diameter, Southern
ScientiﬁcSupplies,Lancing,UK).Theanimalwasreturnedto
thehomecageandallowedtomovefreelyduringtheinjection
and diffusion process. All substances were injected in a total
volume of 2 or 5 ml (depending on solubility) over a period of
30 s, with a further 30 s allowed for complete diffusion. After
injection, the injection needle was removed from the guide
cannula and the home cage returned to the holding room.
Experiment 1 Mice (nZ12–16/group) were administered
either vehicle (0.9% saline; 5 ml i.c.v.) or a-helical CRF9–41
(25 mg; 5 ml i.c.v.), followed 30 min later by administration of
pGlu-apelin-13 (1 mg/kg; 2 ml i.c.v.) or vehicle (0.9% saline;
2 ml i.c.v.) and killed 30 min later.
Experiment 2 V1bR KO and wild-type (WT) mice (nZ
9–12/group)wereadministeredpGlu-apelin-13(1 mg/kg;2 ml
i.c.v.)or vehicle(0.9%saline; 2 mli.c.v.)and killed 30 minlater.
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administered either vehicle (0.9% saline; 5 ml i.c.v.) or
a-helical CRF9–41 (25 mg; 5 ml i.c.v.), followed 30 min later
by administration of pGlu-apelin-13 (1 mg/kg; 2 ml i.c.v.) or
vehicle (0.9% saline; 2 ml i.c.v.) and killed 30 min later.
Peptides
pGlu-apelin-13 was purchased from Bachem (St Helens,
UK). a-helical CRF9–41 was purchased from Phoenix
Pharmaceuticals (Burlingame, CA, USA). All peptides were
made up fresh in 0.9% sterile physiological saline (pH 5) on
the day of the experiment and kept on ice until use.
Hormone analysis
All experiments were performed at least twice and hormone
concentrations in samples were measured in duplicate. Mice
were killed by decapitation and trunk blood was collected
into chilled heparinised tubes. Plasma was obtained by
centrifugation and stored at K20 8C until assayed for ACTH
and CORT. Total plasma ACTH concentration was
quantiﬁed using a two-site ELISA kit (IDS, Tyne & Wear,
UK) with a sensitivity of 0.46 pg/ml and intra-assay
variation of !10% (supplier’s product data (http://www.
idsltd.com/Downloads/)). Plasma concentrations of CORT
were measured using an enzyme immunoassay (EIA) kit
(IDS). The sensitivity is 0.55 ng/ml with an intra-assay
variation of !10% (product data at: http://www.idsltd.
com/Downloads/AC-14PL.pdf ). For both ACTH ELISA
and CORT EIA, absorbance readings were taken at 450 nm
using a Versamax plate reader (Molecular Devices
Corporation, Sunnyvale, CA, USA).
Statistical analysis
Hormone concentrations are expressed as a percentage of
baseline of saline-treated control animals. All results are
expressed as meanGS.E.M. Where appropriate, plasma
hormone concentrations were analysed by one-way
ANOVA followed by Dunnett’s post hoc using GraphPad
Prism(version4.0b)software(GraphPadSoftware,SanDiego,
CA, USA). P!0.05 was considered statistically signiﬁcant.
Effects of genotype and treatment were determined by
two-way ANOVA with repeated measures and subsequent
post hoc tests as appropriate.
Results
Experiment 1: effect of a-helical CRF9–41 on pGlu-apelin-13
stimulated plasma ACTH and CORT
To investigate whether apelin has a central role in regula-
ting CRF neurons, the effect of i.c.v. administration of
pGlu-apelin-13 on neuroendocrine function in mice
pre-treated with the CRF receptor antagonist, a-helical
CRF9–41, was determined. Absolute levels of ACTH secreted
after administration of saline were 50G24 pg/ml. Adminis-
tration of pGlu-apelin-13 (1 mg/kg i.c.v.) resulted in a
statistically signiﬁcant increase in ACTH (202.2G29.3%
of saline control; see Fig. 1A). This effect was blocked by
pre-treatment with a-helical CRF9–41 (25 mg; 5 ml i.c.v.),
which reduced the ACTH response to 97.4G8.3% of
saline-treated animals. Administration of a-helical CRF9–41
alonehadnosigniﬁcanteffectonplasmaACTH(77G12.0%),
when compared with saline controls.
The effect of pGlu-apelin-13 on plasma CORT is shown in
Fig. 1B. Absolute levels of CORT secreted after adminis-
tration of saline were 73G17 ng/ml. pGlu-apelin-13 admin-
istration (1 mg/kg i.c.v.) resulted in a signiﬁcant increase in
CORT (189.5G15.3%) compared with saline-injected
controls. This increase in plasma CORT was signiﬁcantly
reduced by pre-treatment with a-helical CRF9–41
(25 mg; 5 ml i.c.v.) to 129G16% of saline-treated control.
Figure 1 The effect of a-helical CRF9–41 on pGlu-apelin-13
stimulated plasma ACTH and CORT. Pre-treatment with a-helical
CRF9–41 (ah-CRF) blocked the pGlu-apelin-13-induced increase in
(A) ACTH and (B) CORT concentrations in male mice. Animals
received either a-helical CRF9–41 (25 mg; 5 ml i.c.v.) or vehicle
(0.9% saline; 5 ml i.c.v.), followed 30 min later by administration of
pGlu-apelin-13 (1 mg/kg; 2 ml i.c.v.) or vehicle (0.9% saline; 2 ml
i.c.v). Data are expressed as meanGS.E.M.* * P!0.01, one-way
ANOVA followed by Dunnett’s post hoc test.
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alone had no signiﬁcant effect on plasma CORT (107.4
G15.4%) when compared with saline controls.
Experiment 2: effect of pGlu-apelin-13 on plasma ACTH
and CORT in WTand V1bR KO mice
The potential role of apelin in regulating AVP neurones was
investigated by determining the effect of i.c.v. administration
of pGlu-apelin-13 on neuroendocrine function in V1bR KO
mice (Fig. 2). There was no signiﬁcant effect of genotype on
the plasma ACTH response to administration of saline.
Absolute levels of ACTH secreted after administration of
saline were WT 50G24 versus KO 59G16 pg/ml plasma;
PO0.05, two-way ANOVA. After administration of
pGlu-apelin-13 (1 mg/kg i.c.v.), a signiﬁcant increase in
plasma ACTH was seen in WT (231.9G24.4%) but not
in V1bR KO (119.5G16.6%) mice compared with WT
control (Fig. 2A).
The effect of pGlu-apelin-13 administration (1 mg/kg
i.c.v.) on plasma CORT in WTand V1bR KO mice is shown
in Fig. 2B. As for ACTH, there was no signiﬁcant effect of
genotype on plasma CORTresponse to the administration of
saline, WT 73G17 ng/ml plasma versus KO 109G24 ng/ml
plasma; PO0.05, two-way ANOVA. Administration of
pGlu-apelin-13 (1 mg/kg i.c.v.) resulted in a signiﬁcant
increase in plasma CORT in both WTand V1bR KO mice;
however, this CORT response to pGlu-apelin-13 was
signiﬁcantly reduced in V1bR KO compared with WT
mice (WT 554.3G41.1% versus V1bR KO 402.3G28.9%;
P!0.01).
Experiment 3: effect of a-helical CRF9–41 on pGlu-apelin-13
stimulated plasma CORT in V1bR KO mice
To investigate whether the CORT response seen after the
administration of pGlu-apelin-13 to V1bR KO mice is due to
an involvement of CRF-mediated actions, the effect of i.c.v.
administration of pGlu-apelin-13 on the CORT response of
V1bR KO mice pre-treated with a-helical CRF9–41 was
determined. The CORT response to pGlu-apelin-13 alone
was similar to that seen in experiment 2 with an increase to
408.8G63.3% of baseline control. This increase in CORT
secretion was unaffected by pre-treatment with a-helical
CRF9–41 (359.0G30.7%; P!0.001; Fig. 3).
Discussion
The present study demonstrates that the in vivo effects of
apelin on HPA axis neuroendocrine function are mediated
through both CRF- and AVP-dependent mechanisms.
pGlu-apelin-13 activation of the HPA axis, as evidenced by
an increase in plasma ACTH and CORT in control animals,
was signiﬁcantly attenuated both in mice pre-treated with
the CRF receptor antagonist, a-helical CRF9–41, and in mice
lacking functional AVP V1b receptors.
In the HPA axis, localisation of apelin and APJ mRNA and
protein to hypothalamic nuclei known to contain AVP and
CRF, and to modulate HPA endocrine responses to stress, has
generated interest in a role for apelin in the regulation of HPA
axis activity. Apelin may possibly act by controlling
hypothalamic neuropeptide synthesis or release in parvo-
cellular AVP and/or CRF neurones, to directly or indirectly
alter ACTH secretion. However, apelin may also have a direct
effect on HPA axis activity at the pituitary corticotroph level,
as the peptide and receptor are both co-localised with ACTH
in corticotrophs suggesting autocrine and/or paracrine
interactions between apelin and ACTH. Our previous work
suggested aspects of the apelinergic system present in the
hypothalamus to be involved in the modulation of stress
responses, as restraint stress was shown to be associated with
Figure 2 Effect of pGlu-apelin-13 on plasma ACTH and CORT
in wild-type (white bars) and V1bR KO mice (black bars).
(A) Administration of pGlu-apelin-13 (1 mg/kg; 2 ml i.c.v.) resulted
in a signiﬁcant increase in plasma ACTH in wild-type but not in
V1bR KO mice. (B) Administration of pGlu-apelin-13 (1 mg/kg; 2ml
i.c.v.) resulted in a signiﬁcant increase in plasma CORT in both
wild-type and V1bR KO mice; however, the CORT response to
pGlu-apelin-13 was signiﬁcantly reduced in V1bR KO compared to
wild-typemice. Dataare expressedas meanGS.E.M.
CCCP!0.001,
**P!0.01 two-way ANOVA using Bonferroni post hoc test.
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(O’Carroll et al. 2003). Removal of endogenous glucocorti-
coids by adrenalectomy resulted in an increased expression of
APJ mRNA in the pPVN, implying negative regulation of
APJ mRNA expression by glucocorticoids (O’Carroll et al.
2003). After repeated restraint stress, there was a sustained
increase in expression of APJ mRNA in the pPVN, similar to
that observed for AVP mRNA (De Goeij et al. 1992),
suggesting that apelin acting through APJ facilitates parvo-
cellular function under conditions of repeated stress. While
CRF is the major activator of pituitary corticotroph ACTH
secretion in acute stress, AVP appears to be important in
maintaining the HPA axis response to a number of repeated
and chronic stressors (Harbuz & Lightman 1992, Aguilera
1994), and, although both pituitary CRFR1 receptors and
AVP V1b receptors are activated and undergo regulatory
variations during stress, only the changes in V1b receptor
levels parallel the changes in pituitary ACTH responsiveness
(Rabadan-Diehl et al. 1995, Aguilera & Rabadan-Diehl
2000). Recent studies, however, in V1bR KO receptor-
deﬁcient mice, have substantiated the role of AVP in the HPA
axis response to some acute stressors (Lolait et al. 2007a,b,
Stewart et al. 2008).
Previous studies involving central administration of
pGlu-apelin-13 have focussed on the activity of this peptide
in the regulation of a broad range of homeostatic behaviours
in the rat, notably food (Sunter et al. 2003) and water intake
(Reaux et al. 2001,Taheri et al. 2002), or cardiovascular effects
(Kagiyama et al. 2005). Few studies have investigated the role
of central apelin and APJ in neuroendocrine activation as
reﬂected by ACTH and CORT secretion (Taheri et al. 2002,
Jaszberenyi et al. 2004). Central administration of pGlu-
apelin-13 has been shown to activate PVN neurones and to
stimulate the HPA axis as indicated by increased c-fos
expression in the PVN (Kagiyama et al. 2005), and increased
secretion of both ACTH and CORT into the plasma (Taheri
et al. 2002). Additionally, apelin appears to have a central role
in the regulation of AVP and CRF neurones, as apelin
stimulated release of both of these peptides from hypo-
thalamic explants in vitro (Taheri et al. 2002). Recently, in
an in vitro perfusion system of anterior pituitaries, apelin-17
signiﬁcantly increased basal ACTH secretion (Reaux-Le
Goazigo et al. 2007).
This study represents the ﬁrst in vivo investigation of the
mechanism of action of pGlu-apelin-13 on the secretion of
ACTH and CORT in the mouse. We investigated whether
pGlu-apelin-13 may exert its actions via stimulation of the
release of CRF from neurones of the pPVN, which acts on
the anterior pituitary to stimulate the secretion of ACTH into
the periphery, resulting in the secretion of CORT from the
adrenal glands. We show that pre-treatment of mice with the
CRF receptor antagonist, a-helical CRF9–41, attenuated
the pGlu-apelin-13-induced elevations in plasma ACTH and
CORT observed in control mice to levels seen in saline
controls. This result is in agreement with a study performed
onratswhere apelin-evoked CORTsecretion was diminished
by pre-treatment with a-helical CRF9–41 ( Jaszberenyi et al.
2004). Our data clearly indicate that apelin may exert its
effects through CRF-dependent mechanisms; however, the
role of additional mediators such as AVP cannot be excluded.
The relative contributions of AVP and CRF in activation of
the HPA axis depend on the nature of the stimulus, but it is
well established that both peptides are required for a full
ACTH response to many acute stressors (Kjaer et al. 1992,
Suda et al. 1992).
In the neurohypophysial system, the physiological effects of
apelin appear to be mediated by AVP. We and others have
found apelin and APJ to be expressed within a proportion of
magnocellular PVN (mPVN) and SON vasopressinergic
neurones (Reaux et al. 2001, O’Carroll & Lolait 2003), where
the two peptides are segregated within separate subcellular
compartments (Reaux-Le Goazigo et al. 2004), suggesting an
interaction between the apelinergic and vasopressinergic
systems in the regulation of body ﬂuid homeostasis. Recent
studies report a cross-regulation of endogenous levels of
apelin and AVP (Reaux-Le Goazigo et al. 2004), and that
apelin acts to regulate AVP actions through modulation of
AVP neurone activity and AVP release (Reaux-Le Goazigo
et al. 2004, Tobin et al. 2008). Interestingly, there is
unequivocal evidence that the neurohypophysial and HPA
axes functionally overlap and that AVP produced in the
mPVN contributes to the regulation of HPA axis activity
(secretion of ACTH; reviewed in Engelmann et al. 2004).
Moreover, some stressors that activate the HPA axis appear to
preferentially activate mPVN more than pPVN AVP
neurones e.g. forced swim test (Engelmann et al. 2004).
In order to determine the role of AVP in the mechanism
of action of pGlu-apelin-13 in activation of the HPA axis,
pGlu-apelin-13 was administered to both WTand V1bR KO
mice. These mice have impaired HPA responses to a number
of stress models (Lolait et al. 2007a,b, Stewart et al. 2008),
Figure 3 Effect of a-helical CRF9–41 on pGlu-apelin-13 stimulated
plasma CORTin V1bR KO mice. Administration of pGlu-apelin-13
(1 mg/kg; 2 ml i.c.v.) resulted in a signiﬁcant increase in plasma
CORTin V1bR KO mice that was not blocked by pre-treatment with
a-helical CRF9–41(ah-CRF)(25 mg; 5 ml i.c.v.). Dataare expressed as
meanGS.E.M.* * P!0.01 one-way ANOVA followed by Dunnett’s
post hoc test; ns, not signiﬁcant.
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However, we have shown no difference in basal or CRF-
stimulated ACTH release from anterior pituitary tissue from
V1bR KO or WT mice, suggesting that there is no difference
in pituitary sensitivity to CRF between genotypes (Lolait
et al. 2007a). Additionally, in the same study, we have shown
basal levels of AVP, oxytocin and CRF gene expression in the
hypothalamic PVN, and pro-opiomelanocortin (the pre-
cursor for ACTH) gene expression in the anterior pituitary to
be similar in V1bR KO and WT mice implying no evidence
of compensatory gene expression to the genetic change. In
this present study, administration of pGlu-apelin-13 resulted
in a signiﬁcant increase in plasma ACTH in WT mice, an
effect that was abolished in V1bR KO mice, indicating a
signiﬁcant role for the V1bR in the ACTH response to apelin
administration. The absence of an ACTH response in these
mutant mice suggests that the stimulatory effect of apelin on
CRF release cannot by itself manifest afull ACTHresponse to
apelin administration. Interestingly, V1bR KO mice had a
markedly diminished, although not absent, CORT response
to pGlu-apelin-13 administration. Dissociation between
ACTH and CORT responses to stimulation in V1bR KO
animals has been observed previously, albeit in different
experimental models (acute lipopolysaccharide challenge
(Lolait et al. 2007b), acute and chronic forced swimming
and acute and chronic restraint stress (Stewart etal. 2008)). It is
possible that ACTH levels in V1bR KO mice, however
low, are still high enough to induce a normal CORT
response to stress, or that the residual adrenal activity may
be mediated by ACTH-independent CORT modulators.
Pituitary-independent factors that may modulate adrenal
CORT secretion include sympathetic activity (Bornstein &
Chrousos 1999, Droste et al. 2007) and cytokines such as
interleukin-6 (Bornstein & Chrousos 1999). Levels of CORT
secretion in V1bR KO mice did not change when animals
were pre-treated with a-helical CRF9–41, indicating that the
remaining levels of CORT cannot be attributed to the action
of CRF on CRF pituitary receptors.
In conclusion, our data suggest that apelin, mediating its
effects through activation of paraventricular CRF and AVP
neurones, requires both CRF and AVP for a full ACTH and
CORTresponse and that neither can compensate for the loss
of the other in maintaining a normal HPA axis response to
apelin. We cannot exclude the possibility, however,that apelin
injected i.c.v. in these studies reaches the anterior pituitary
and/orothersitesthatmayinﬂuenceHPAaxisactivitytoexert
a direct effect. Our results emphasise an interaction between
apelin and paraventricular AVP and CRF and suggest that the
integration of neurobehavioural responses to stress is more
complicated than previously envisioned.
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